Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.
Griffiths B, Emery P, Ryan V, Isenberg D, Akil M, Thompson R, Maddison P, Griffiths ID, Lorenzi A, Miles S, Situnayake D, Teh LS, Plant M, Hallengren C, Nived O, Sturfelt G, Chakravarty K, Tait T, Gordon C. Griffiths B, et al. Among authors: griffiths id. Rheumatology (Oxford). 2010 Apr;49(4):723-32. doi: 10.1093/rheumatology/kep396. Epub 2010 Jan 16. Rheumatology (Oxford). 2010. PMID: 20081225 Clinical Trial.
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators. Jani M, et al. Arthritis Rheumatol. 2015 May;67(8):2011-9. doi: 10.1002/art.39169. Arthritis Rheumatol. 2015. PMID: 26109489 Free PMC article.
Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.
Hyrich KL, Watson KD, Lunt M, Symmons DP; British Society for Rheumatology Biologics Register (BSRBR). Hyrich KL, et al. Rheumatology (Oxford). 2011 Jan;50(1):117-23. doi: 10.1093/rheumatology/keq209. Epub 2010 Jul 29. Rheumatology (Oxford). 2011. PMID: 20671021 Free PMC article.
Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity.
Hyrich KL, Deighton C, Watson KD; BSRBR Control Centre Consortium; Symmons DP, Lunt M; British Society for Rheumatology Biologics Register. Hyrich KL, et al. Rheumatology (Oxford). 2009 Oct;48(10):1323-7. doi: 10.1093/rheumatology/kep242. Epub 2009 Aug 25. Rheumatology (Oxford). 2009. PMID: 19706737 Free PMC article. Clinical Trial.
Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.
Bluett J, Ibrahim I, Plant D, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD; BRAGGSS; Barton A. Bluett J, et al. Pharmacogenomics J. 2014 Apr;14(2):171-5. doi: 10.1038/tpj.2013.26. Epub 2013 Jul 16. Pharmacogenomics J. 2014. PMID: 23856853 Free PMC article.
131 results